Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 75Paclitaxel 68Bevacizumab 44Taxes 22Cyclophosphamide 21pembrolizumab 19Gemcitabine 19Cisplatin 18Topotecan 17Hyperthermic Intraperitoneal Chemotherapy 14olaparib 13liposomal doxorubicin 13Immunoglobulin G 13Disulfides 13Specimen Handling 11Drug Therapy 11niraparib 10Cytoreduction Surgical Procedures 10Magnetic Resonance Spectroscopy 9sargramostim 7Surveys and Questionnaires 7Doxorubicin 7Docetaxel 7durvalumab 6Platinum 6Nivolumab 6Letrozole 6Granulocyte-Macrophage Colony-Stimulating Factor 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fallopian Tube Neoplasms × birinapant × Clear all
NCT02756130 2025-05-13

Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Jonsson Comprehensive Cancer Center

Phase 1/2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡